costs of venetoclax-obinutuzumab vs. btki in cll | scott huntington, md, mph, msc | ash 2023
Published 9 months ago • 601 plays • Length 2:57Download video MP4
Download video MP3
Similar videos
-
4:08
what is chronic lymphocytic leukemia #cll?
-
8:16
venetoclax and obinutuzumab in cll
-
1:36
dr. davids on cost effectiveness of time-limited therapy with venetoclax/obinutuzumab in cll
-
24:09
update on venetoclax for cll
-
4:10
ibrutinib and venetoclax continue to provide benefits for patients with chronic cll and sll
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
9:15
obinutuzumab venetoclax for frontline cll
-
1:36
obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in cll
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
1:22
first-in-human study of tg-1801, a cd19/cd47 bispecific antibody ± ublituximab in bcl
-
5:59
6-year results of cll14: venetoclax-obinutuzumab for previously untreated cll
-
2:02
important prognostic factors to evaluate in cll patients in the era of small molecules
-
1:34
time-limited vs continuous therapy in cll treatment
-
5:07
cd20-targeted antibodies with novel agents for cll
-
0:47
alpine results: zanubrutinib vs. ibrutinib in cll
-
1:40
cll11 trial shows improved os rates in cll with obinutuzumab
-
3:03
the evolution of treatment patterns and prognostic biomarkers in latin american cll patients
-
1:31
can ibrutinib be used as a first-line treatment in cll?